Accelerating Motor Recovering in Patients With SMA Syndrome After Glioma Surgery by Using nrTMS

Last updated: April 30, 2023
Sponsor: Beijing Neurosurgical Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Brain Cancer

Brain Tumor

Cancer/tumors

Treatment

TMS stimulation sham-treatment

TMS stimulation treatment

Clinical Study ID

NCT05803057
8220101798
  • Ages 25-55
  • All Genders

Study Summary

The goal of this randomized clinical controlled trial is to learn about whether neuro-navigation repetitive transcranial magnetic stimulation (nrTMS) was useful to accelerate the recovery in patients with SMA syndrome after glioma resection. The main questions aim to answer:

  • Question 1: Whether the nrTMS was useful to accelerate the recovery of motor function back to the preoperative status in participants with SMA syndrome after glioma resection.

  • Question 2: Whether the nrTMS was useful to improve postoperative motor function in participants with SMA syndrome after glioma resection.

Participants will continue to receive nrTMS treatment or nrTMS sham-treatment for 7 times on the 8th day after glioma resection to determine whether the TMS was helpful for exercise rehabilitation. The investigator will evaluate the effects of nrTMS treatment through the ratio of recovery of motor function and the time that was from the participants suffering SMA syndrome to totally recover the motor function to the status of motor function in pre-operation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Inpatients in neurosurgery oncology wards of Beijing Tiantan Hospital
  • Right-handed, age: 25-55 years old
  • Tumor located in supplementary motor area
  • No previous treatment history of central nervous system disease
  • The patient received awaken craniotomy
  • Pathological diagnosis is low grade glioma
  • Volunteer to accept nrTMS treatment

Exclusion

Exclusion Criteria:

  • The tumor grows across the midline to the opposite side
  • Regarding rs-fMRI data, head movement exceeds 1mm and head deflection exceeds 1 °
  • The patient did not have SMA syndrome after operation
  • Vulnerable or special groups and protective measures, such as pregnant women

Study Design

Total Participants: 64
Treatment Group(s): 2
Primary Treatment: TMS stimulation sham-treatment
Phase:
Study Start date:
April 01, 2023
Estimated Completion Date:
March 31, 2025

Study Description

This study will use the 8-coil (Magstem, England, No.4150) and sham 8-coil (Magstem, England) The criteria of enrolled patients are： A. Inclusion time: from April 01 2023 to March 31 2025 (including the current month); B. Inpatients in neurosurgery oncology wards of Beijing Tiantan Hospital; C. Right-handed, age: 25-55 years old, tumor located in SMA, no previous treatment history of nervous system disease; D. The patient received wake-up surgery and applied direct cortical electrical stimulation during the operation to determine the location of the motor area; E. Postoperative pathology was low grade glioma; F. Can accept nrTMS rehabilitation treatment.

The excluding criteria are:

A. The tumor grows across the midline to the opposite side; B. When collecting rs-fMRI data, head movement exceeds 1mm and head deflection exceeds 1 °; C. The patient did not have SMA syndrome after operation; D. Vulnerable or special groups and protective measures, such as pregnant women.

Connect with a study center

  • Beijing Neurosurgical Institute and Beijing Tiantan Hospital

    Beijing, Beijing 100005
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.